Search Results

CSL Seqirus will manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. government’s pandemic preparedness activities

https://www.seqirus.us/news/csl-seqirus-us-government-award-to-manufacture-and-assess-influenza-a-h5n8-pre-pandemic-vaccine

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news

CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.us/expertise

Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA)

https://www.seqirus.us/news/seqirus-and-us-gov-renew-multi-year-agreement-for-influenza-pandemic-preparedness-and-response

Seqirus is officially recognized by the U.S. government as having successfully established domestic manufacturing capability for innovative cell-based seasonal and pandemic influenza vaccines.

https://www.seqirus.us/news/seqirus-holly-springs-manufacturing-facility-designated-by-us-government-as-pandemic-ready

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

https://www.seqirus.us/news/csl-enters-licensing-agreement-arcturus-therapeutics-next-gen-mrna-vaccine-technology

CSL Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.us/expertise/influenza/pandemic-response-solutions

New data will be presented at the Options for the Control of Influenza (OPTIONS XI) conference taking place September 26-29, 2022 in Belfast, United Kingdom.

https://www.seqirus.us/news/seqirus-to-highlight-commitment-to-influenza-protection-with-data-presentations-at-options-xi

The new pre-filled syringe line has received FDA approval and will support influenza vaccine production for the 2022/23 Northern Hemisphere season and beyond.

https://www.seqirus.us/news/seqirus-completes-$156-million-expansion-to-hsp-manufacturing-facility

Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives

https://www.seqirus.us/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines